Marizyme Inc, a medical devices developer, has filed Form S-1 Registration Statement on January 14, 2022 with the U.S. Securities and Exchange Commission to raise up to $17 million IPO. Pricing terms are yet to announce.
The company is a multi-technology life science company dedicated to the acceleration, development and commercialization of medical technologies that promote patient health and present potential for rapid revenue growth. Currently, they are focused on developing three medical technology platforms – DuraGraft, MATLOC and Krillase.
The Jupiter, Florida-based company was founded in 2007 and plans to list on the Nasdaq Capital Market under the symbol “MRZM.” Univest Securities is the underwriter of the IPO.
The company engages Bevilacqua PLLC as US Securities Counsel, and WithumSmith+Brown, PC as Independent Auditor.
#ipo #nasdaq #medical #Marizyme #device #developer #platform #technologies #science
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
